Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Should Colchicine Become Standard Therapy for CAD?

Canadian Collaborative Research Network

P. Ridker

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Lipids Update: Current Guidelines for Lipid Management

Scripps Health

S. R. Mehta

Cardiology’s Biggest Controversy: The Lumen or the Wall - the Curiou…

Cedars Sinai

J. Forrester

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

Plant Based Living: Exponential Growth in Acceptance and Knowledge

3rd Annual Montefiore Einstein Preventive Cardiology Conference

A. Freeman

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

ESC 2024 Insights: Comparison of Different Calcium Modification Stra…

ESC 2024 Insights

K. Yasumura

TCT 2024 Insights: A Contemporary Analysis and Outcomes of Orbital A…

TCT 2024 Insights

H. Amin

DAPT Following ACS: Does One Size Fit All?

Canadian Collaborative Research Network

M. Bonaca

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

Basics of OCT Imaging

FACET

N. Pinilla-Echeverri

TCT 2024 Insights: Insights from the DanGer Shock and ECLS-Shock Tri…

TCT 2024 Insights

G. Tarantini

Lipid Lowering Therapies: Where Did We Start, Where We Are Now and W…

The Texas Heart Institute

S. Virani

Q&A: Are We Underusing CABG?

Cedars Sinai

J. Chikwe

Cholesterol Update: LDL and Lp (a)

Cleveland Clinic Heart, Vascular and Thoracic Institute

S. Nissen